KẾT QUẢ ĐIỀU TRỊ BỔ TRỢ UNG THƯ ĐẠI TRÀNG GIAI ĐOẠN II NGUY CƠ CAO, III BẰNG PHÁC ĐỒ CÓ OXALIPLATIN TẠI BỆNH VIỆN E

Abstract

Objectives: Describe some clinical and laboratory characteristics of patients with high- risk stage II and III colon cancer receiving adjuvant Oxaliplatin-containing regimen at E Hospital. Evaluation of treatment results of the study group of patients. Subjects and research methods: Retrospective description of 66 patients were diagnosed with colon cancer high-risk stage II and III colon cancer, underwent radical surgery, and received adjuvant chemotherapy after surgery by oxaliplatin-containing regimen at E Hospital from January 2018 to December 2023. Results: The medium age was 62,83. Male/female: 1,13. The most common tumor site was the sigma colon 40,9%. The most tumor gross type was protruded 40,9%. The highest proportion of adenocarcinoma was 78,8%. Major histological grade was grade 2 (90,9%). Disease-free survival (DFS) rate at 3 years was 79,6%. Overall survival (OS) rates at 3 years, 4 years and 5 years were 86,9%, 83,1% and 78,9%. In XELOX group, 4 years OS were 89,8% and 68,1%. There is no difference in OS between two groups. Conclusion: Oxaliplatin-containing regimen improve DFS and OS in adjuvant therapy for high-risk stage II and III colon cancer